India considers allowing import of raw material for manufacturing crude heparin
Heparin and its related derivative, the low molecular weight heparin, also known as enoxaparin, is an anticoagulant that has demonstrated its effectiveness in treatment of patients infected with Covid-19 virus during the ongoing pandemic. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 3, 2020 Category: Pharmaceuticals Source Type: news

What are the risk factors and effectiveness of prophylaxis for venous thromboembolism in COVID-19 patients?, CEBM
This study identified a paucity of evidence for both the risks factors of VTE and the effectiveness of prophylactic strategies to prevent VTE in COVID-19 patients. Potential risk factors which were identified for thrombolytic events include older age and higher levels of D-dimer, though the actual threshold for a high level D-dimer varied between studies. Commonly encountered prophylactic strategies which were; low molecular weight heparin (LMWH) or unfractionned heparin, nadroparin and enoxaparin. A number of studies found that despite prophylaxis there was still a high incidence of thrombolytic complications in COVID-1...
Source: Current Awareness Service for Health (CASH) - July 13, 2020 Category: Consumer Health News Source Type: news

Enoxaparin in acute coronary syndromes: better outcomes, lower cost
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 1, 2020 Category: Drugs & Pharmacology Source Type: news

Rivaroxaban Prevents VTE After Lower - Limb Surgery
Rivaroxaban superior to enoxaparin for preventing major VTE after nonmajor orthopedic surgery (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - April 3, 2020 Category: Respiratory Medicine Tags: Internal Medicine, Emergency Medicine, Oncology, Orthopedics, Pharmacy, Pulmonology, Surgery, Journal, Source Type: news

Rivaroxaban Prevents VTE After Lower-Limb Surgery
FRIDAY, April 3, 2020 -- Following nonmajor orthopedic surgery of the lower limb, rivaroxaban is superior to enoxaparin for prevention of major venous thromboembolism, according to a study published online March 29 in the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 3, 2020 Category: Pharmaceuticals Source Type: news

PRONOMOS: Rivaroxaban Bests Enoxaparin for VTE Prophylaxis PRONOMOS: Rivaroxaban Bests Enoxaparin for VTE Prophylaxis
New trial results show rivaroxaban was not only noninferior but superior to enoxaparin in reducing venous thromboembolism after nonmajor orthopedic surgery.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 30, 2020 Category: Consumer Health News Tags: Cardiology News Source Type: news

29.03.20: Not intended for U.S. and UK Media - New study results add to solid evidence for the efficacy and safety of Rivaroxaban in the prevention of venous thromboembolism:
Rivaroxaban significantly reduced risk of major venous thromboembolism following nonmajor orthopaedic surgeryData from PRONOMOS study published in The New England Journal of Medicine and presented during a virtual session of the American College of Cardiology's 69th Annual Scientific Session together with World Congress of Cardiology (ACC.20/WCC Virtual) / The first study to demonstrate that a Factor Xa inhibitor was superior to enoxaparin in reducing risk of major venous thromboembolism in adult patients who have undergone lower limb nonmajor orthopaedic surgery / Bleeding rates were low and not significantly different be...
Source: Bayer IR Newsfeed: Events - March 29, 2020 Category: Pharmaceuticals Source Type: news

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

Tailored Doses of Enoxaparin Better Prevent VTE After Cancer Surgery Tailored Doses of Enoxaparin Better Prevent VTE After Cancer Surgery
Adjusting the doses of enoxaparin based on anti-Xa levels, instead of using standard doses, may better prevent venous thromboembolism (VTE) without worsening bleeding rates in patients undergoing abdominal cancer surgery, according to a new study.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - January 18, 2020 Category: Surgery Tags: General Surgery News Source Type: news

NASA Astronaut Had The First Known Blood Clot In Space
(CNN) — When astronauts encounter a medical risk on the International Space Station 250 miles up from the Earth’s surface, it’s not exactly easy for a doctor to make a house call. So when NASA researchers suspected a blood clot in one of their astronauts during a long-duration stay on the space station last year, they had to act quickly to treat the unexpected risk. The blood clot was detected during a vascular study of 11 astronauts on the station to assess the effect of space on the internal jugular vein. In zero gravity, astronauts’ blood and tissue fluid shifts toward the head. The study involve...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - January 5, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Offbeat Syndicated CBSN Boston CNN International Space Station NASA Source Type: news

Enoxaparin cost effective after non-orthopaedic surgery in China
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 1, 2019 Category: Drugs & Pharmacology Source Type: news

Fixed-Dose Enoxaparin Prophylaxis Often Inadequate for Colorectal Surgery Fixed-Dose Enoxaparin Prophylaxis Often Inadequate for Colorectal Surgery
Most patients undergoing colorectal surgery don't get adequate anticoagulation from the FDA-approved 40 mg daily dose of enoxaparin, possibly setting the stage for breakthrough venous thromboembolism, researchers say.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - June 3, 2019 Category: Surgery Tags: General Surgery News Source Type: news

Class 4 Medicines Defect Information: Inhixa solution for injection in pre-filled syringe (enoxaparin sodium)
The Medicines and Healthcare products Regulatory Agency (MHRA) has issues a Class 4 medicines defect information drug alert for Inhixa solution for injection in pre-filled syringes. (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - April 18, 2018 Category: Drugs & Pharmacology Source Type: news

U.S. jury sides with Amphastar over Momenta in drug patent trial
BOSTON (Reuters) - A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox. (Source: Reuters: Health)
Source: Reuters: Health - July 21, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Oral Apixaban Safe for Thromboprophylaxis Before Surgery in Gynecologic Cancers
Thromboprophylaxis with oral apixaban was similar to subcutaneous enoxaparin with regard to safety outcomes in women undergoing surgery for suspected gynecologic malignancies. (Source: CancerNetwork)
Source: CancerNetwork - March 17, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Cancer Complications Gynecologic Cancers News Conferences/SGO 2017 Source Type: news

Lovenox (Enoxaparin Sodium Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 11, 2017 Category: Drugs & Pharmacology Source Type: news

Enoxaparin preferred option for VTE prevention after THR in China
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2017 Category: Drugs & Pharmacology Source Type: news

Betrixaban in Acutely Ill Bests Enoxaparin Against Strokes: APEX Betrixaban in Acutely Ill Bests Enoxaparin Against Strokes: APEX
The finding in patients hospitalized for acute illness was said to be"a wake-up message" that even those admitted for ischemic stroke or heart failure are at special risk for thrombosis."Heartwire from Medscape (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - November 29, 2016 Category: Intensive Care Tags: Cardiology News Source Type: news

ENSURE-AF Trial Supports Edoxaban for Electrical Cardioversion
ROME — Results of the largest-ever randomized clinical trial of anticoagulation for electrical cardioversion of patients with nonvalvular atrial fibrillation demonstrate that edoxaban is a safe, effective, and convenient alternative to the standard strategy of enoxaparin as a bridge to warfarin. (Source: Caring for the Ages)
Source: Caring for the Ages - September 29, 2016 Category: Health Management Authors: Bruce Jancin Source Type: news

Blood Clots, Deep Vein Thrombosis and Pulmonary Embolism
What is Deep Vein Thrombosis (DVT)? DVT is the formation of a blood clot (thrombus) within a deep vein. The deep veins pass through deep tissues and muscles. Muscle contractions (walking, running, activity, etc.) squeeze blood through the deep veins to the heart. The deep veins have valves which prevent blood from flowing back to the ankles and feet. The majority of blood clots are small and are usually broken down or dissolved. Large clots may form and can block the vein causing the patient to complain of pain and swelling. Homan's sign is not very specific. High index of suspicion is necessary for diagnosis. Virchow'...
Source: Healthy Living - The Huffington Post - August 17, 2016 Category: Consumer Health News Source Type: news

No significant difference in the risk of Acute Coronary Syndrome (including Myocardial Infarction) seen with Pradaxa < sup > ® < /sup > (dabigatran etexilate) compared to enoxaparin for VTE prevention after orthopaedic surgery
No significant difference in the risk of Acute Coronary Syndrome (including Myocardial Infarction) seen with Pradaxa ® (dabigatran etexilate) compared to enoxaparin for VTE prevention after orthopaedic surgery (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Enoxaparin Adjustment Curbs Thromboembolism in Trauma PatientsEnoxaparin Adjustment Curbs Thromboembolism in Trauma Patients
In trauma patients, compared to use of standard prophylactic doses of enoxaparin sodium, dosage adjustment prompted by anti-factor Xa (anti-Xa) trough levels may reduce venous thromboembolism (VTE), according to California-based researchers. Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - July 15, 2016 Category: Surgery Tags: Emergency Medicine News Source Type: news

Enoxaparin Adjustment Curbs Thromboembolism in Trauma Patients Enoxaparin Adjustment Curbs Thromboembolism in Trauma Patients
In trauma patients, compared to use of standard prophylactic doses of enoxaparin sodium, dosage adjustment prompted by anti-factor Xa (anti-Xa) trough levels may reduce venous thromboembolism (VTE), according to California-based researchers. Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - July 15, 2016 Category: Surgery Tags: Emergency Medicine News Source Type: news

Apologizing for medical errors
Question: A patient was admitted with heart failure, developed deep vein thrombosis, and was started on warfarin and Lovenox as “bridge” therapy. On day 4, the patient achieved anticoagulation... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - July 7, 2016 Category: Endocrinology Source Type: news

Apologizing for medical errors
Question: A patient was admitted with heart failure, developed deep vein thrombosis, and was started on warfarin and Lovenox as “bridge” therapy. On day 4, the patient achieved anticoagulation... (Source: Pediatric News)
Source: Pediatric News - July 7, 2016 Category: Journals (General) Source Type: news

Apologizing for medical errors
Question: A patient was admitted with heart failure, developed deep vein thrombosis, and was started on warfarin and Lovenox as “bridge” therapy. On day 4, the patient achieved anticoagulation... (Source: Clinical Neurology News)
Source: Clinical Neurology News - July 7, 2016 Category: Neurology Source Type: news

Apologizing for medical errors
Question: A patient was admitted with heart failure, developed deep vein thrombosis, and was started on warfarin and Lovenox as “bridge” therapy. On day 4, the patient achieved anticoagulation... (Source: Family Practice News)
Source: Family Practice News - July 7, 2016 Category: Primary Care Source Type: news

Medical errors and the law
Question: A patient was admitted with heart failure, developed deep vein thrombosis, and was started on warfarin and Lovenox as “bridge” therapy. On day 4, the patient achieved anticoagulation... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - July 7, 2016 Category: Endocrinology Source Type: news

Medical errors and the law
Question: A patient was admitted with heart failure, developed deep vein thrombosis, and was started on warfarin and Lovenox as “bridge” therapy. On day 4, the patient achieved anticoagulation... (Source: Pediatric News)
Source: Pediatric News - July 7, 2016 Category: Journals (General) Source Type: news

Medical errors and the law
Question: A patient was admitted with heart failure, developed deep vein thrombosis, and was started on warfarin and Lovenox as “bridge” therapy. On day 4, the patient achieved anticoagulation... (Source: Clinical Neurology News)
Source: Clinical Neurology News - July 7, 2016 Category: Neurology Source Type: news

APEX: Hopeful Sign Despite Betrixaban Miss for VTE PreventionAPEX: Hopeful Sign Despite Betrixaban Miss for VTE Prevention
The novel oral agent didn't win out over enoxaparin in the trial's primary cohort but did in the larger overall cohort; the later finding was exploratory but convincing nonetheless, say researchers. Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 7, 2016 Category: Consumer Health News Tags: Cardiology News Source Type: news

Betrixaban scores near miss for extended thromboprophylaxis
Extended thromboprophylaxis with the direct factor Xa inhibitor betrixaban just fails to show superiority to standard treatment with enoxaparin in acutely ill medical patients. (Source: MedWire News)
Source: MedWire News - May 31, 2016 Category: Consumer Health News Tags: Thrombosis Source Type: news

Enoxaparin Cost-Effective for Post-Cystectomy VTE Prevention (CME/CE)
(MedPage Today) -- Prophylaxis lowered overall costs, study finds (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 9, 2016 Category: Cardiology Source Type: news

Enoxaparin Sodium Injection (New - Discontinuation)
Updated Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - March 4, 2016 Category: Drugs & Pharmacology Source Type: news

Teva Bolsters Injectable Portfolio With Launch Of Generic Lovenox And Generic Zyvox In The United States
Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, recently announced the launch of the generic equivalent of Lovenox (enoxaparin sodium injection) in seven dosage strengths in the United States (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - February 23, 2015 Category: Pharmaceuticals Source Type: news

Daiichi Sankyo Begins Phase 3 Study For Edoxaban
Daiichi Sankyo announced that it has initiated enrollment of patients into the multinational Phase III study ENSURE-AF evaluating the safety and efficacy of edoxaban against enoxaparin and warfarin. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - April 4, 2014 Category: Pharmaceuticals Source Type: news

FDA Underlines Risk of Spinal Procedures on LMW HeparinsFDA Underlines Risk of Spinal Procedures on LMW Heparins
The FDA announced new recommendations aimed at reducing the risk of spinal bleeding with epidural and lumbar puncture procedures among patients taking enoxaparin and other low-molecular-weight heparins. News Alerts (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 6, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

FDA updates warning on Sanofi's blood thinner Lovenox
(Reuters) - The U.S. Food and Drug Administration issued a new warning on the use of the anticoagulant Lovenox in patients fitted with a spinal catheter because of the risk of spinal column bleeding and potential paralysis. (Source: Reuters: Health)
Source: Reuters: Health - November 6, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Bleed Risk Falls with Bivalirudin en Route to PCI for STEMIBleed Risk Falls with Bivalirudin en Route to PCI for STEMI
Some will recognize shades of HORIZONS AMI: the gains came from bivalirudin vs heparin or enoxaparin for STEMI, initiated in EUROMAX while patients were in an ambulance en route to a PCI center. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 30, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Apixaban: Effective in Acute VTE; Lower Risk of Major Bleeding
The novel anticoagulant can now be considered for both acute and extended treatment of VTE, with a lower risk of major bleeding than standard treatment with enoxaparin and warfarin. (Source: Consultant Live)
Source: Consultant Live - July 18, 2013 Category: Primary Care Source Type: news

Apixaban vs Standard Anticoagulation in Acute VTEApixaban vs Standard Anticoagulation in Acute VTE
The oral factor Xa inhibitor was noninferior for efficacy and led to a 69% drop in major bleeding complications in patients with acute deep vein thrombosis or pulmonary embolism, compared with enoxaparin followed by warfarin. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 1, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

AMPLIFY: Apixaban in acute VTE as effective but safer than standard anticoagulation
The oral factor Xa inhibitor was noninferior for efficacy and led to a 69% drop in major bleeding complications in patients with acute deep vein thrombosis or pulmonary embolism, compared with enoxaparin followed by warfarin. (Source: theHeart.org)
Source: theHeart.org - July 1, 2013 Category: Cardiology Source Type: news

STREAM Trial Data Supports An Early Fibrinolysis-Based Strategy For Patients With STEMI Who Cannot Undergo Primary PCI
New data published in NEJM demonstrates that patients with STEMI who cannot undergo primary PCI within 60 minutes of first medical contact have similar clinical outcomes with early fibrinolysis with Metalyse® (tenecteplase, TNK-tPA) in combination with clopidogrel and enoxaparin, followed by timely angiography (pharmaco-invasive strategy), compared to patients given primary PCI after the 60-minute window.(1) "In STEMI patients, the most important thing is to re-establish blood supply to the heart... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 25, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

NEJM Paper Confirms Value Of Early Fibrinolysis In STEMI
New England Journal of Medicine (NEJM) paper shows prehospital or early fibrinolysis with Metalyse® (tenecteplase) delivers comparable clinical outcomes to gold standard intervention for patients who would not have access to primary PCI within 60 minutes after the first medical contact(b) New data published in NEJM demonstrates that patients with STEMI who cannot undergo primary PCI within 60 minutes of first medical contact have similar clinical outcomes with early fibrinolysis with Metalyse® (tenecteplase, TNK-tPA) in combination with clopidogrel and enoxaparin... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 22, 2013 Category: Consumer Health News Tags: Heart Disease Source Type: news

RCT: Rivaroxaban for thromboprophylaxis in acutely ill medical patients (MAGELLAN)
Source: N Engl J Med Area: News RCTs of hospitalised patients at increased risk for venous thromboembolism (VTE) have shown the benefits of administering anticoagulant agents for up to 14 days. There is some evidence that the risk of VTE in acutely ill medical patients persists after hospital discharge, but no studies have supported the routine use of extended thromboprophylaxis.   Rivaroxaban is an oral, direct factor Xa inhibitor that is used for the prevention of VTE after elective hip-replacement or knee-replacement surgery in adults. The 'Multicenter, Randomised, Parallel Group Efficacy and Safety Study for ...
Source: NeLM - Cardiovascular Medicine - February 7, 2013 Category: Cardiology Source Type: news

Rivaroxaban Noninferior to Enoxaparin in VTE Prophylaxis, but at a Cost
(Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 7, 2013 Category: Primary Care Tags: Medical News Source Type: news

Rivaroxaban Reduces VTE Risk in Acutely Ill PatientsRivaroxaban Reduces VTE Risk in Acutely Ill Patients
Rivaroxaban was noninferior to enoxaparin for the prevention of asymptomatic proximal or symptomatic venous thromboembolism at day 10 and was superior to enoxaparin for the prevention of the same clinical events at day 35. Treatment with the new oral anticoagulant was associated with a significantly increased risk of bleeding at day 10 and day 35, however. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 6, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

MAGELLAN published: Rivaroxaban reduces VTE risk in acutely ill patients
Rivaroxaban was noninferior to enoxaparin for the prevention of asymptomatic proximal or symptomatic venous thromboembolism at day 10 and was superior to enoxaparin for the prevention of the same clinical events at day 35. Treatment with the new oral anticoagulant was associated with a significantly increased risk of bleeding at day 10 and day 35, however. (Source: theHeart.org)
Source: theHeart.org - February 6, 2013 Category: Cardiology Source Type: news